KK
ELVN icon

KLP Kapitalforvaltning’s Enliven Therapeutics ELVN Stock Holding History

KLP Kapitalforvaltning’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Buy
12,300
+5,500
+81% +$233K ﹤0.01% 1407
2026
Q1 		$267K Hold
6,800
– – ﹤0.01% 1707
2025
Q4 		$105K Hold
6,800
– – ﹤0.01% 2066
2025
Q3 		$139K Hold
6,800
– – ﹤0.01% 1962
2025
Q2 		$136K Buy
6,800
+2,500
+58% +$47.3K ﹤0.01% 1922
2025
Q1 		$84.6K Hold
4,300
– – ﹤0.01% 2084
2024
Q4 		$96.8K Buy
+4,300
New +$111K ﹤0.01% 2101

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

KLP Kapitalforvaltning's ELVN Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Enliven Therapeutics (ELVN) stake by 81% in Q2 2026, buying an estimated $233K and bringing the position to 12,300 shares worth $624K. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

KLP Kapitalforvaltning first reported a position in ELVN in Q4 2024 and has held it in 7 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • KLP Kapitalforvaltning held 12,300 shares of Enliven Therapeutics worth $624K as of Q2 2026.
  • KLP Kapitalforvaltning bought 5,500 Enliven Therapeutics shares in Q2 2026, an estimated $233K.
  • Enliven Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1407 holding.
  • KLP Kapitalforvaltning first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.